ArticleTranslational vision science & technology2025
Preclinical Evaluation of a Pilocarpine-(R)-Lipoic Acid Eye Drop for Presbyopia.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Presbyopia is a progressive, age-related loss of near vision. Although current therapies offer symptomatic relief, they fail to target the underlying pathology. These studies investigated a novel dual-mechanism eye drop, CLX-162 (pilocarpine lipoate salt), focusing on three key characteristics: (1) tolerability, (2) pharmacokinetics and ocular tissue penetration, and (3) chemical stability within a dual-chamber delivery system. Methods: Tolerability and pharmacokinetic studies involved administering CLX-162 and lipoic acid choline ester (LACE) ophthalmic formulations to New Zealand White rabbits. Investigators assessed ocular tolerability using the Draize scoring system and evaluated pharmacokinetics by collecting and analyzing ocular tissues. A third study evaluated CLX-162 stability by storing it in a dual-chamber system under varying conditions and analyzing the drug substance and reconstituted product. Results: CLX-162 demonstrated superior ocular tolerability compared to LACE, with no corneal, iridial, or conjunctival effects observed. It induced transient pupillary constriction, whereas LACE caused mild redness and discharge. Pharmacokinetic analysis showed that CLX-162 achieved significantly higher and longer lasting (R)-lipoic acid levels in the aqueous humor and lens than LACE. Pilocarpine remained detectable for up to 8 hours. Stability studies confirmed that CLX-162 retained potency for 6 months in the dual-chamber container, with pilocarpine and (R)-lipoic acid levels within 95% to 100%. After reconstitution, it remained stable for 21 days. Conclusions: These preclinical studies demonstrated the stability, penetrability, and safety of CLX-162 dispensed in a dual-chamber, supporting progression to clinical trials. Translational Relevance: The dual-mechanism design of CLX-162 addresses the oxidative stress-driven lens changes underlying presbyopia, bridging preclinical findings to future patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.